EU approves Ongentys (opicapone) to treat adult Parkinson's disease patients with motor fluctuations.- Bial
BIAL announced that the medicinal product Ongentys (opicapone) for the treatment of adult Parkinson's disease patients with motor fluctuations was approved by the European Commission. BIAL will make Ongentys available for Parkinson's disease patients during 2016 and 2017 across Europe. Ongentys is indicated as adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCIs) in adult patients with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilized on those combinations.
Comment: Ongentys has the ability to decrease off-time (time when patients are severely restricted by their symptoms) and increase on-time without troublesome dyskinesia.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins